
Allergan has announced another move in its “refreshment” of its executive Board of Directors with the appointment of Thomas C …

Teva has been doing some major global restructuring since Kare Schultz came to the helm of the embattled, Israeli drugmaker. …

Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …

Researchers at King’s College London (KCL) have made significant progress to being able to offer a treatment to those with …

Claire Young explores her family’s journey through the diagnosis of her son George, who lives with Batten disease, a form …

Roche has lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), …

A study that thoroughly analyses the impact of Sanofi’s dengue vaccine has confirmed what was feared – children without prior …

The FDA has rejected Mylan’s generic version of GlaxoSmithKline’s Advair for the second time following its knockback last year, citing …

The NHS’ recruitment crisis has been on-going for a number of years, with an ageing population and a higher workload …

Arriving at a particularly low point for the reputation of the biotech, after STAT revealed that a party at BIO …

A new report from communications and research agencies GK Strategy and onefourzero has revealed the massive extent to which consumer …

The anti-vaxxer movement is the scourge of meticulously researched science and yet, in certain states in the US, it seems …

Celgene has seized the opportunity at the Annual European Congress of Rheumatology in Amsterdam to reveal positive new data for …

Just last week, Johnson & Johnson announced that it had received an offer from Fortive for its medical sterilisation unit, …

Defeating the ageing process is a pie-in-the-sky idea that has resulted, so far, in a rich vein of parody rather …

The Brexit decision has created a huge amount of question marks for many industries and each is vying with each …

Research emerging from two studies, published in same issue of Nature, has raised significant questions over just how safe CRISPR …

San Diego-based biopharma firm Vical has announced the disappointing, if unsurprising, news that it has taken the decision to terminate …

Allergan has made ground in its quest to become “the headache company” with the release of new Phase 2b/3 data …

Finding a treatment for Alzheimer’s disease has been one of the aims of big pharma for last few decades, but …